Login to Your Account



BioSante Turns to Nonprofit for Melanoma Vaccine Development

By Catherine Shaffer


Friday, July 22, 2011
As a way of getting clinical trials "under way and successfully concluded," BioSante Pharmaceuticals Inc., of Lincolnshire, Ill., has licensed its melanoma vaccine to the John P. Hussman Foundation for $100,000 up front, with up to $39 million in milestones.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription